前列腺素E1治疗慢性病毒性肝炎,肝硬化及重症肝炎的疗效

目的：进一步探讨前列腺Ｅ１（ＰＧＥ１）对病毒性肝炎的疗效。方法：对９５例慢性乙型肝炎、肝炎肝硬化及重症肝炎在综合护肝治疗的基础上加用ＰＧＥ１治疗，疗程１４～２１ｄ，另设对照组９０例。ＰＧＥ１治疗组中血清总胆红素（ＳＢ）的降低明显优于对照组（Ｐ〈０．０５）。在慢性肝炎病例组中，治疗组中ＡＬＴ的下降显著低于对照组（Ｐ〈０．０５）；而在重症肝炎组中，虽然两组的病死率无显著性差异，但治疗组中〖凝血〗因子Ⅱ

Clinical observation on the effects of prostaglandin El in patients with chronic viral hepatitis, hepatic cirrhosis and severe hepatitis

AIM: To study the effects of prostaglandin El (PGE1) on viral hepatitis. METHODS: Ninety-five patients of chronic hepatitis B, hepatic cirrhosis and severe hepatitis were treated with PGEl for 14~20 d. 90 cases were given a general liver protective therapy as control. RESULTS: The total serum bilirubin (SB) in the group of cases who were treated with PGEl was significantly lower than that of the control group (P<0. 05). The ALT of the chronic hepatitis cases in the former group was significantly lower than that of the latter group (P<0. 05). Although the fatality rates were not found significantly differences between 2 groups of cases of severe hepatitis, the FTA and recovery rates in the group of PGEl treatment were significantly higher than that of the group of control (P<0. 05). CONCLUSION: PGEl is effective to decline SB and ALT in chronic hepatitis, hepatic- 211 -cirrhosis and severe hepatitis, and it is helpful for the recovery of severe hepatitis.